|
October 5, 2000
First International Conference on Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy
The First International Conference on Cerebral Amyloid Angiopathy (CAA) is being hosted
by the Massachusetts General Hospital in Boston. Supported by Neurochem Inc., a Canadian
based industry leader in biopharmaceuticals, this is the first conference to discuss possible
therapeutic prevention trials for hemorrhagic stroke associated with CAA, for which there
is no present therapy. The conference will be held at the Royal Sonesta Hotel in Boston
from October 5-6, 2000.
" This conference is unique in that it is the first aimed specifically at identifying
effective treatments for this debilitating disease," said Dr. Steven M. Greenberg,
Assistant Professor of Neurology at Harvard Medical School, Co-Director of the Neurology
Clinical Trials Unit at the Massachusetts General Hospital, and chairman of the
conference.
"We are encouraged to see a conference of this calibre focus on a disease which is
one of the major target diseases for Neurochem," said Dr. Louis R. Lamontagne,
President and CEO of Neurochem Inc. "This meeting should help us advance the
development of a therapeutic treatment for patients suffering from this disease."
Hemorrhagic stroke due to Cerebral Amyloid Angiopathy, is characterized by the progressive
invasion of the blood vessel wall by amyloid fibrils, which can lead to small stokes and
potentially devastating lobar hemorrhages in the brain. It is considered the only major
type of stroke for which there is no effective treatment. This conference will allow doctors
and scientists to come together to discuss a framework for drug trials for this serious
disease. Under the Honorary Chair of Dr. Alan S. Cohen, from the Boston University School
of Medicine, the program will feature 18 internationally recognized physicians and scientists
speaking on a variety of aspects of CAA.
Neurochem is an industry leader in the development of a novel, proprietary series of
compounds that inhibit the formation, deposit and toxic effects of amyloid fibrils on
cells within the body. Neurochem's research team has been working with international
amyloid experts on the development of therapeutic cures to amyloid-related diseases,
including Alzheimer's disease, Secondary Amyloidosis , Diabetes Type II and Hemorrhagic
Stroke (due to Cerebral Amyloid Angiopathy). Neurochem has advanced three drug candidates to
clinical trials: Alzhemed™, for the treatment of Alzheimer's disease,
Fibrillex™, for Secondary Amyloidosis, and Cerebril™, for
Hemorrhagic Stroke. At present, the Company employs over 50 people and is located in
Saint-Laurent, Canada (www.neurochem.com).
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
